Medpace Q3 Revenue Rises 8.5%, Approves $1B Buyback
Medpace reported Q3 2026 revenue of $716.0 million, up 8.5% year over year, and GAAP EPS of $4.84. Backlog increased to $3.17 billion, and the company reaffirmed 2026 revenue guidance of $2.835 billion–$2.855 billion and GAAP net income guidance of $514 million–$524 million.
Medpace reported Q3 2026 revenue of $716.0M, an 8.5% increase YoY, and GAAP EPS of $4.84. Backlog reached $3.17B, and the company approved a new stock repurchase authorization of up to $1.0B. Medpace reaffirmed its 2026 guidance, projecting revenue of $2.835B—$2.855B and GAAP net income of $514M—$524M.